Metlife Inc (MET) receives a strong valuation ranking of 77 from InvestorsObserver's data analysis. The proprietary ranking system focuses on the underlying health of a company through analysis of its stock price, earnings, and growth rate. MET has a better value than 77% of stocks based on these valuation analytics. Investors primarily focused on buy-and-hold strategies will find the valuation ranking relevant to their goals when making investment decisions.
MET's trailing-12-month Price to Earnings (PE) ratio of 5.1 puts it below the historical average of roughly 15. MET is a good value at its current trading price as investors are paying less than what its worth in relation to the company's earnings. MET's trailing-12-month earnings per share (EPS) of 7.73 does justify what it is currently trading at in the market. Trailing PE ratios, however, do not factor in a company's projected growth rate, resulting in some firms having high PE ratios due to high growth potentially enticing investors even if current earnings are low.
MET's 12-month-forward PE to Growth (PEG) ratio of 1.63 is considered a poor value as the market is overvaluing MET in relation to the company's projected earnings growth due. MET's PEG comes from its forward price to earnings ratio being divided by its growth rate. A PEG ratio of 1 represents a perfect correlation between earnings growth and share price. Due to their incorporation of more fundamentals of a company's overall health and focusing on the future rather than the past, PEG ratios are one of the most used valuation metrics by analysts today.
MET' has a weak valuation at its current share price on account of a overvalued PEG ratio due to strong growth. MET's PE and PEG are worse than the market average leading to a below average valuation score.